| AJTR Copyright © 2009-All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711 |
Am J Translational Res 2011;3(3):269-274
Review Article
Rabbit monoclonal antibody: potential application in cancer therapy
Lifeng Feng, Xian Wang, Hongchuan Jin
Laboratory of Cancer Epigenetics, Biomedical Research Center, Sir Runrun Shaw Hospital, School of Medicine,
Zhejiang University, Hangzhou, 310016, China
Received April 6, 2011; accepted April 19, 2011; Epub April 23, 2011; Published May 15, 2011
Abstract: By targeting antigens specifically, monoclonal antibodies represent a new class of therapeutic agents
for the clinical management of various diseases including cancers. Monoclonal antibody technology has been
greatly developed by reducing murine content in antibodies to minimize side effects in clinical applications.
However, several intrinsic disadvantages of antibodies with murine origin limit the clinical efficacy of monoclonal
antibodies based targeted therapy. The development of rabbit monoclonal antibody technology provides an
alternative source of monoclonal antibodies with higher specificity and less cost for the development of routine
targeted therapy against cancers. (AJTR1104001).
Keywords: Monoclonal antibody, rabbit monoclonal antibody, cancer therapy
Full Text PDF
Address all correspondence to:
Dr. Xian Wang
Laboratory of Cancer Epigenetics
Biomedical Research Center
Sir Runrun Shaw Hospital, School of Medicine
Zhejiang University, Hangzhou, 310016, China
Tel: +86 571 8600 6926; Fax: +85 571 8600 5145
Email: wangx118@yahoo.com;
Dr. Hongchuan Jin
Laboratory of Cancer Epigenetics
Biomedical Research Center
Sir Runrun Shaw Hospital, School of Medicine
Zhejiang University, Hangzhou, 310016, China
Tel: +86 571 8600 6366; Fax: +86 571 8600 6145
Email: jinhc@srrsh.com
Review Article
Rabbit monoclonal antibody: potential application in cancer therapy
Lifeng Feng, Xian Wang, Hongchuan Jin
Laboratory of Cancer Epigenetics, Biomedical Research Center, Sir Runrun Shaw Hospital, School of Medicine,
Zhejiang University, Hangzhou, 310016, China
Received April 6, 2011; accepted April 19, 2011; Epub April 23, 2011; Published May 15, 2011
Abstract: By targeting antigens specifically, monoclonal antibodies represent a new class of therapeutic agents
for the clinical management of various diseases including cancers. Monoclonal antibody technology has been
greatly developed by reducing murine content in antibodies to minimize side effects in clinical applications.
However, several intrinsic disadvantages of antibodies with murine origin limit the clinical efficacy of monoclonal
antibodies based targeted therapy. The development of rabbit monoclonal antibody technology provides an
alternative source of monoclonal antibodies with higher specificity and less cost for the development of routine
targeted therapy against cancers. (AJTR1104001).
Keywords: Monoclonal antibody, rabbit monoclonal antibody, cancer therapy
Full Text PDF
Address all correspondence to:
Dr. Xian Wang
Laboratory of Cancer Epigenetics
Biomedical Research Center
Sir Runrun Shaw Hospital, School of Medicine
Zhejiang University, Hangzhou, 310016, China
Tel: +86 571 8600 6926; Fax: +85 571 8600 5145
Email: wangx118@yahoo.com;
Dr. Hongchuan Jin
Laboratory of Cancer Epigenetics
Biomedical Research Center
Sir Runrun Shaw Hospital, School of Medicine
Zhejiang University, Hangzhou, 310016, China
Tel: +86 571 8600 6366; Fax: +86 571 8600 6145
Email: jinhc@srrsh.com
 | |  | |  | |  | |  | |  | |  |